Skip to main content
Top
Published in: Sports Medicine 6/2003

01-05-2003 | Leading Article

Marijuana as Doping in Sports

Authors: Daniel R. Campos, Mauricio Yonamine, Regina L. de Moraes Moreau

Published in: Sports Medicine | Issue 6/2003

Login to get access

Abstract

A high incidence of positive cases for cannabinoids, in analyses for doping control in sports, has been observed since the International Olympic Committee (IOC) included them in the 1989 list of prohibited drugs under the title of classes of prohibited substances in certain circumstances. Where the rules of sports federations so provide, tests are conducted for marijuana, hashish or any other cannabis product exposure by means of urinalysis of 11-nor-delta-9-tetrahydro-cannabinol-9-carboxylic acid (carboxy-THC) the main metabolite of delta-9-tetrahydrocannabinol (THC). Concentrations >15 ng/mL (cut-off value) in confirmatory analytical procedures are considered doping. Cannabis is an illicit drug in several countries and has received much attention in the media for its potential therapeutic uses and the efforts to legalise its use.
Studies have demonstrated that the use of cannabinoids can reduce anxiety, but it does not have ergogenic potential in sports activities. An increase in heart rate and blood pressure, decline of cardiac output and reduced psychomotor activity are some of the pharmacological effects of THC that will determine a decrease in athletic performance. An ergolytic activity of cannabis products has been observed in athletes of several different sport categories. In Brazil, analyses for doping control in sports, performed in our laboratories, have detected positive cases for carboxy-THC in urine samples of soccer, volleyball, cycling and other athletes.
It is our intention to discuss in this article some points that may discourage individuals from using cannabis products during sports activities, even in the so-called permitted circumstances defined by the IOC and some sports federations.
Footnotes
1
The use of tradenames is for product identification purposes only and does not imply endorsement.
 
Literature
1.
go back to reference Verroken M. Drug use and abuse in sport. J Clin Endocrinol 2001; 14(1): 1–23 Verroken M. Drug use and abuse in sport. J Clin Endocrinol 2001; 14(1): 1–23
3.
go back to reference International Olympic Committee. Prohibited classes of substances and prohibited methods. Lausanne: International Olympic Committee, 1999 International Olympic Committee. Prohibited classes of substances and prohibited methods. Lausanne: International Olympic Committee, 1999
4.
go back to reference Drumer OH. The forensic pharmacology of drugs of abuse. London: Arnold, 2001 Drumer OH. The forensic pharmacology of drugs of abuse. London: Arnold, 2001
5.
go back to reference Frank M, Rosenthal E. Marijuana growers guide. Berkeley (CA): And/Or Press, 1978 Frank M, Rosenthal E. Marijuana growers guide. Berkeley (CA): And/Or Press, 1978
6.
go back to reference Reinhardt VED, Midio AF. Características botânicas,químicas e produtos obtidos da Cannabis. Rev Farm Bioquim Univ Sao Paulo 1993; 29(2): 55–61 Reinhardt VED, Midio AF. Características botânicas,químicas e produtos obtidos da Cannabis. Rev Farm Bioquim Univ Sao Paulo 1993; 29(2): 55–61
8.
go back to reference Wall ME, Brine DR, Pit CG, et al. Identification of delta-9-te-trahydrocannabinol and metabolites in man. J Am Chem Soc 1972; 94(24): 8579–81PubMedCrossRef Wall ME, Brine DR, Pit CG, et al. Identification of delta-9-te-trahydrocannabinol and metabolites in man. J Am Chem Soc 1972; 94(24): 8579–81PubMedCrossRef
9.
go back to reference Porter AC, Felder CC. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 2001; 90: 45–60PubMedCrossRef Porter AC, Felder CC. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 2001; 90: 45–60PubMedCrossRef
10.
go back to reference Pertwce RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74(2): 129–80CrossRef Pertwce RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74(2): 129–80CrossRef
11.
go back to reference Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91(11): 1585–614PubMedCrossRef Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91(11): 1585–614PubMedCrossRef
12.
go back to reference Johansson EK, Hollister LE, Halldin MM. Urinary elimination half-life of delta-1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. NIDA Res Monogr 1989; 95: 457–8PubMed Johansson EK, Hollister LE, Halldin MM. Urinary elimination half-life of delta-1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. NIDA Res Monogr 1989; 95: 457–8PubMed
13.
go back to reference Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992; 16(4): 228–35PubMed Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992; 16(4): 228–35PubMed
14.
go back to reference Huestis MA, Mitchell JM, Cone EJ. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 1995; 19(6): 443–9PubMed Huestis MA, Mitchell JM, Cone EJ. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 1995; 19(6): 443–9PubMed
15.
go back to reference Huestis MA, Mitchell JM, Cone EJ. Urinary excretion profiles of 11-nor-delta-9-carboxy-tetrahydrocannabinol in humans after single smoke doses of marijuana. J Anal Toxicol 1996; 20(6): 441–52PubMed Huestis MA, Mitchell JM, Cone EJ. Urinary excretion profiles of 11-nor-delta-9-carboxy-tetrahydrocannabinol in humans after single smoke doses of marijuana. J Anal Toxicol 1996; 20(6): 441–52PubMed
16.
go back to reference Caplan YH. Workplace testing. In: Karch SB, editor. Drug abuse handbook. Boca Raton (FL): CRC Press, 1998: 738 Caplan YH. Workplace testing. In: Karch SB, editor. Drug abuse handbook. Boca Raton (FL): CRC Press, 1998: 738
17.
go back to reference Mareck-Engelke U, Geyer H, Schanzer W. Misuse of cannabinoids in high level competitions. Deutsche Zeitschrift fur Sportmedizin 2001; 52(10): 280–4 Mareck-Engelke U, Geyer H, Schanzer W. Misuse of cannabinoids in high level competitions. Deutsche Zeitschrift fur Sportmedizin 2001; 52(10): 280–4
19.
Metadata
Title
Marijuana as Doping in Sports
Authors
Daniel R. Campos
Mauricio Yonamine
Regina L. de Moraes Moreau
Publication date
01-05-2003
Publisher
Springer International Publishing
Published in
Sports Medicine / Issue 6/2003
Print ISSN: 0112-1642
Electronic ISSN: 1179-2035
DOI
https://doi.org/10.2165/00007256-200333060-00001

Other articles of this Issue 6/2003

Sports Medicine 6/2003 Go to the issue

Review Article

Warm Up I